Skin and Mucosal Human Papillomavirus Seroprevalence in Persons with Fanconi Anemia

Persons with Fanconi anemia (FA) are at risk for human papillomavirus (HPV)-associated cancers; however, their natural HPV exposure and infection rates are unknown as is the adequacy with which they mount antibodies to HPV vaccination. This study aimed to determine, in 62 persons with FA, the seroprevalence of skin andmucosal HPV types, the seroprevalence in individuals self-reporting a history of HPV vaccination, and the factors associated with HPV seropositivity. A bead Luminex assay was used to determine seropositivity for HPV1,-2, and-4 (low-risk skin),-6 and-11 (low-risk mucosal, included in one HPV vaccine),-16 and-18 (high-risk mucosal, included in both HPV vaccines), and-52 and-58 (high-risk mucosal). Health- and behavior-related questionnaires were completed. Type-specific seroprevalence estimates and participant characteristics associated with sero-prevalence were calculated; 48 % reported HPV vaccination. Type-specific seropositivity in unvaccinated persons ranged from 7 to 21 % for skin HPV types and 7 to 38 % for mucosal HPV types. Among the unvaccinated participants, adults versus childre